{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:44:50Z","timestamp":1791074690912,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Japanese Ministry of Health, Labor, and Welfare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ymgme.2012.05.005","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T09:34:11Z","timestamp":1337333651000},"page":"122-128","source":"Crossref","is-referenced-by-count":46,"title":["Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II"],"prefix":"10.1016","volume":"107","author":[{"given":"Takashi","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Kawagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohta","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Hirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.05.005_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0015","first-page":"253","article-title":"Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome)","volume":"15","author":"Papadia","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5301\/HIP.2011.8826","article-title":"Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patients","volume":"21","author":"Donaldson","year":"2011","journal-title":"Hip Int."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-011-0236-5","article-title":"Enzyme replacement therapy for Pompe disease","volume":"12","author":"Angelini","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0030","first-page":"172","article-title":"Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy","volume":"2","author":"Desnick","year":"2006","journal-title":"Nephrol. Ther."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0035","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1167\/iovs.10-6751","article-title":"Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy","volume":"11","author":"Newkirk","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10545-011-9280-1","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points","volume":"34","author":"Glamuzina","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"12","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","article-title":"Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed","volume":"31","author":"Al Sawaf","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/dmd.111.042903","article-title":"Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse","volume":"40","author":"Zhou","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis","volume":"69","author":"Tsuji","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/hmg\/ddl038","article-title":"Correction of Hunter syndrome in the MPSII mouse model by AAV2\/8-mediated gene delivery","volume":"1","author":"Cardone","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymgme.2007.03.003","article-title":"Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II","volume":"91","author":"Garcia","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00431766","article-title":"Y-maze behavior in the mouse after morphine or an enkephalin analog","volume":"74","author":"Schmaltz","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ymgme.2012.05.005_bb0085","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1161\/STROKEAHA.110.583948","article-title":"Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion","volume":"41","author":"Washida","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2012.05.005_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2011.05.020","article-title":"Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells","volume":"104","author":"Kawagoe","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2011.10.038","article-title":"Proteasome inhibitors improve the function of mutant lysosomal \u03b1-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation","volume":"18","author":"Shimada","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/NEN.0b013e3181db7d3c","article-title":"Expression of hydroxyindole-O-methyltransferase enzyme in the human central nervous system and in pineal parenchymal cell tumors","volume":"69","author":"Fukuda","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2230.1999.00448.x","article-title":"Skin eruption as the presenting sign of Hunter syndrome IIB","volume":"24","author":"Demitsu","year":"1999","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0115","first-page":"56","article-title":"Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey","volume":"23","author":"Link","year":"2010","journal-title":"Orthop. Rev. (Pavia)"},{"key":"10.1016\/j.ymgme.2012.05.005_bb0120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10545-007-0641-8","article-title":"The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome)","volume":"30","author":"Garcia","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajhg.2009.07.011","article-title":"IDS crossing of the blood\u2013brain barrier corrects CNS defects in MPSII mice","volume":"85","author":"Polito","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10059-010-0083-2","article-title":"Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2\/8 vector-mediated gene therapy","volume":"30","author":"Jung","year":"2010","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ymgme.2012.05.005_bb0135","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1093\/hmg\/ddq420","article-title":"Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy","volume":"15","author":"Polito","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ymgme.2009.07.015","article-title":"Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II","volume":"98","author":"Wang","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0248-8663(06)80005-6","article-title":"Clinical aspects of early-stage neurological forms of Gaucher disease","volume":"1","author":"Mignot","year":"2006","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.ymgme.2012.05.005_bb0150","first-page":"75","article-title":"Krabbe disease: an overview","volume":"47","author":"Pastores","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic leukodystrophy\u2014an update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ymgme.2012.05.005_bb0160","first-page":"49","article-title":"Prenatal diagnosis and genetic counseling of mucopolysaccharidosis type II (Hunter syndrome)","volume":"18","author":"Chen","year":"2007","journal-title":"Genet. Couns."},{"key":"10.1016\/j.ymgme.2012.05.005_bb0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T10:25:35Z","timestamp":1542968735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":33,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1096719212001941"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.05.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}